Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUHAIL H KHADRA

NPI
1487603239
CMS profile
66653
Location
MUNSTER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$794.26

44 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $750.95 42
Debt forgiveness $28.38 1
Entertainment $14.93 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUHAIL H KHADRA

NPI 1487603239 · CMS profile ID 66653

MUNSTER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487603239?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487603239?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487603239?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SUHAIL H KHADRA, NPI 1487603239, CMS profile ID 66653, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1487603239?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

44 matching records · $794.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 44 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–44 of 44.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $10.1312/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827145 CMS
Novartis Pharmaceuticals Corporation $10.9412/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827141 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.0312/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887491917 CMS
Merck Sharp & Dohme LLC $12.8411/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944282469 CMS
Novartis Pharmaceuticals Corporation $13.0811/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827137 CMS
Novartis Pharmaceuticals Corporation $11.0210/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827133 CMS
Novartis Pharmaceuticals Corporation $13.0810/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827129 CMS
Merck Sharp & Dohme LLC $13.3810/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944255379 CMS
E.R. Squibb & Sons, L.L.C. $16.3810/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932939795 CMS
Novartis Pharmaceuticals Corporation $11.2210/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827125 CMS
Kestra Medical Technology Services, Inc. $16.8409/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904837731 CMS
W. L. Gore & Associates, Inc. $15.9009/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948319251 CMS
Novartis Pharmaceuticals Corporation $13.7509/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827121 CMS
Kestra Medical Technology Services, Inc. $19.2108/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904837735 CMS
Novartis Pharmaceuticals Corporation $11.2208/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827117 CMS
Novartis Pharmaceuticals Corporation $11.1508/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827113 CMS
Kestra Medical Technology Services, Inc. $14.9308/03/2022 Entertainment No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904837729 CMS
AstraZeneca Pharmaceuticals LP $12.5107/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915390665 CMS
Kestra Medical Technology Services, Inc. $49.3207/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904837743 CMS
Kestra Medical Technology Services, Inc. $40.3706/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904837741 CMS
Novartis Pharmaceuticals Corporation $9.8806/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827109 CMS
W. L. Gore & Associates, Inc. $18.5506/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948319041 CMS
Janssen Pharmaceuticals, Inc $22.2506/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886232417 CMS
Kestra Medical Technology Services, Inc. $12.2406/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904837725 CMS
SANOFI-AVENTIS U.S. LLC $17.3006/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938755545 CMS
Novartis Pharmaceuticals Corporation $11.2206/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827105 CMS
E.R. Squibb & Sons, L.L.C. $13.8406/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932939763 CMS
Kestra Medical Technology Services, Inc. $22.9805/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904837739 CMS
Novartis Pharmaceuticals Corporation $18.9305/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827101 CMS
Novartis Pharmaceuticals Corporation $18.9305/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827097 CMS
SANOFI-AVENTIS U.S. LLC $14.6005/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938755541 CMS
Novartis Pharmaceuticals Corporation $8.9904/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827161 CMS
Janssen Pharmaceuticals, Inc $16.9504/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886232425 CMS
Novartis Pharmaceuticals Corporation $10.1304/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827157 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.3104/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887491919 CMS
Novartis Pharmaceuticals Corporation $8.0504/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827153 CMS
Janssen Pharmaceuticals, Inc $18.2403/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886232431 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.8503/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887491921 CMS
Kestra Medical Technology Services, Inc. $69.5902/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904837747 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.3302/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887336079 CMS
Novartis Pharmaceuticals Corporation $13.7502/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893827149 CMS
Janssen Pharmaceuticals, Inc $23.0002/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886232411 CMS
Cardiovascular Systems Inc. $12.6701/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948019863 CMS
Baxter Healthcare $28.3801/06/2022 Debt forgiveness No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 883987161 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $540.50 20
PY2020 $292.38 14
PY2021 $543.76 36
PY2022 $794.26 44
PY2023 $994.78 34
PY2024 $913.91 39
PY2025 $621.54 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,061,757.66 207
PY2024 Principal investigator $654,195.55 69
PY2023 Principal investigator $594,110.73 53
PY2022 Principal investigator $288,215.55 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $435.75 12/31/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
REALIZE-K Phase IV, randomized, double-blind, placebo-controlled, parallel-group trial evaluating Sodium Zirconium Cyclosilicate (SZC) for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction, chronic kidney disease and receiving spironolactone No dispute reported 06/30/2026 1155803054
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,142.31 12/31/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1155803750
Principal investigator 1 Merck Sharp & Dohme LLC $20,205.20 12/31/2024 Non-covered Recipient Entity
Chicago Medical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1136402939
Principal investigator 1 Merck Sharp & Dohme LLC $10,066.86 12/31/2024 Non-covered Recipient Entity
Chicago Medical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1136402943
Principal investigator 1 Merck Sharp & Dohme LLC $4,969.78 12/31/2024 Non-covered Recipient Entity
Chicago Medical Research
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1136403248
Principal investigator 1 PFIZER INC. $1,684.80 12/31/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1130966951
Principal investigator 1 Janssen Research & Development, LLC $5,799.00 12/16/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961929
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,854.60 11/27/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1110848363
Principal investigator 1 Janssen Research & Development, LLC $10,100.00 11/20/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961933
Principal investigator 1 Genentech, Inc. $1,350.00 11/13/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387174
Principal investigator 1 Genentech, Inc. $512.00 11/13/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387176
Principal investigator 1 Genentech, Inc. $6,741.00 11/13/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387178
Principal investigator 1 Genentech, Inc. $252.00 11/13/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387180
Principal investigator 1 Genentech, Inc. $1,350.00 11/13/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387182
Principal investigator 1 Genentech, Inc. $432.00 11/13/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387184
Principal investigator 1 PFIZER INC. $584.55 10/24/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1130993083
Principal investigator 1 Janssen Research & Development, LLC $1,294.00 10/23/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961939
Principal investigator 1 PFIZER INC. $2,197.80 10/11/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1130993077
Principal investigator 1 PFIZER INC. $1,028.70 09/20/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1131013549
Principal investigator 1 Boehringer Ingelheim International GmbH $85,396.40 09/18/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) No dispute reported 06/30/2026 1101070405
Principal investigator 1 Janssen Research & Development, LLC $4,566.00 09/18/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961935
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,885.59 08/23/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1110848203
Principal investigator 1 Janssen Research & Development, LLC $8,215.00 08/19/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961927
Principal investigator 1 Genentech, Inc. $1,248.00 08/09/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387168
Principal investigator 1 Genentech, Inc. $1,248.00 08/09/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387170
Principal investigator 1 Genentech, Inc. $1,466.00 08/09/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387172
Principal investigator 1 PFIZER INC. $3,447.90 08/06/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1131032067
Principal investigator 1 Janssen Research & Development, LLC $8,617.00 07/26/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961923
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $47,169.21 07/18/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) No dispute reported 06/30/2026 1101074861
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 06/19/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961937
Principal investigator 1 Janssen Research & Development, LLC $10,269.00 06/14/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961941
Principal investigator 1 PFIZER INC. $2,864.03 06/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1131066815
Principal investigator 1 Boehringer Ingelheim International GmbH $7,474.36 06/01/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) No dispute reported 06/30/2026 1101070403
Principal investigator 1 PFIZER INC. $7,388.55 06/01/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1131066957
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,704.00 05/31/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
REALIZE-K Phase IV, randomized, double-blind, placebo-controlled, parallel-group trial evaluating Sodium Zirconium Cyclosilicate (SZC) for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction, chronic kidney disease and receiving spironolactone No dispute reported 06/30/2026 1110837418
Principal investigator 1 Janssen Research & Development, LLC $10,043.00 05/22/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961919
Principal investigator 1 Novo Nordisk AS $2,000.00 05/15/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4773 No dispute reported 06/30/2026 1096791177
Principal investigator 1 Novo Nordisk AS $1,170.00 05/13/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1096872699
Principal investigator 1 PFIZER INC. $11,658.00 05/07/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1131079033
Principal investigator 1 Genentech, Inc. $1,464.00 05/03/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387152
Principal investigator 1 Genentech, Inc. $1,329.00 05/03/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387158
Principal investigator 1 Genentech, Inc. $1,664.00 05/03/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387164
Principal investigator 1 Novo Nordisk AS $5,395.62 04/30/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4773 No dispute reported 06/30/2026 1096810875
Principal investigator 1 Janssen Research & Development, LLC $10,532.00 04/26/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961931
Principal investigator 1 Genentech, Inc. $2,247.00 04/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387154
Principal investigator 1 Genentech, Inc. $1,664.00 04/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387156
Principal investigator 1 Genentech, Inc. $1,329.00 04/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387160
Principal investigator 1 Genentech, Inc. $1,329.00 04/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387162
Principal investigator 1 Genentech, Inc. $1,195.00 04/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387166
Principal investigator 1 Novo Nordisk AS $500.00 03/27/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1096746980
Principal investigator 1 Novo Nordisk AS $21,405.00 03/27/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4388 No dispute reported 06/30/2026 1096863484
Principal investigator 1 PFIZER INC. $1,117.80 03/26/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1131097883
Principal investigator 1 Janssen Research & Development, LLC $2,588.00 03/25/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961925
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,418.22 03/12/2024 Non-covered Recipient Entity
Chicago Medical Research, Llc
A Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP (EMBARK-HFpEF) No dispute reported 06/30/2026 1123476520
Principal investigator 1 PFIZER INC. $3,169.80 03/12/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1131098058
Principal investigator 1 Janssen Research & Development, LLC $7,061.00 03/04/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961917
Principal investigator 1 Novo Nordisk AS $187.50 02/23/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4665 No dispute reported 06/30/2026 1096787073
Principal investigator 1 Novo Nordisk AS $2,000.00 02/23/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
EX9536-4665 No dispute reported 06/30/2026 1096861857
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,740.97 02/16/2024 Non-covered Recipient Entity
CHICAGO MEDICAL RESEARCH, LLC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1110838674
Principal investigator 1 PFIZER INC. $3,353.40 01/27/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1131106708
Principal investigator 1 Janssen Research & Development, LLC $9,910.00 01/26/2024 Non-covered Recipient Entity
Chicago Clinic Rsrch Inst Inc.
70033093AFL3002 No dispute reported 06/30/2026 1078961921
Principal investigator 1 Genentech, Inc. $8,988.00 01/19/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387150
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $169,906.85 01/17/2024 Non-covered Recipient Entity
Chicago Medical Research, Llc
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With HFpEF No dispute reported 06/30/2026 1123476522
Principal investigator 1 Genentech, Inc. $88.00 01/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387138
Principal investigator 1 Genentech, Inc. $85.00 01/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387140
Principal investigator 1 Genentech, Inc. $79.00 01/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387142
Principal investigator 1 Genentech, Inc. $123.00 01/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387144
Principal investigator 1 Genentech, Inc. $432.00 01/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387146
Principal investigator 1 Genentech, Inc. $63.00 01/05/2024 Non-covered Recipient Entity
Chicago Medical Research LLC
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1133387148